Pfizer Beefs Up Blood Cancer Pipeline With Trillium Acquisition: See Highlights

  • Pfizer Inc PFE has agreed to acquire Trillium Therapeutics Inc TRIL for $18.50 per share, equivalent to an implied equity value of $2.26 billion.
  • The offer price represents a 118% premium to the 60-day weighted average price for Trillium.
  • Trillium's portfolio includes biologics include immuno-oncology product candidates.
  • Its two lead molecules, TTI-622 and TTI-621, block the signal-regulatory protein α (SIRPα)–CD47 axis, emerging as a key immune checkpoint in hematological malignancies. 
  • TTI-622 and TTI-621 are SIRPα-Fc fusion proteins currently in Phase 1b/2 development across several indications, focusing on hematological malignancies.
  • Related Content: Trillium Therapeutics' CD47 Assets Show Continued Anti-Tumor Activity In Hematologic Malignancies.
  • Pfizer will conduct a webcast at 10:00 a.m. ET today.
  • Price Action: TRIL stock soared 191.50% at $17.75, and PFE stock is up 2.94% at $50.15 during the premarket session on the last check Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechLong IdeasM&ANewsHealth CareSmall CapMoversTrading IdeasGeneralblood cancerBriefsPhase 1 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!